File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma

TitleFerroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma
Authors
KeywordsCancer therapy
Ferroptosis
Hepatocellular carcinoma
Molecular targets
Sorafenib
Issue Date28-Feb-2023
PublisherXIA & HE Publishing Inc.
Citation
Journal of Clinical and Translational Hepatology, 2023, v. 11, n. 1, p. 207-218 How to Cite?
AbstractHepatocellular carcinoma (HCC) is one of the most common and highly heterogeneous malignancies worldwide. Despite the rapid development of multidisciplinary treatment and personalized precision medicine strategies, the overall survival of HCC patients remains poor. The limited survival benefit may be attributed to difficulty in early diagnosis, the high recurrence rate and high tumor heterogeneity. Ferroptosis, a novel mode of cell death driven by iron-dependent lipid peroxidation, has been implicated in the development and therapeutic response of various tumors, including HCC. In this review, we discuss the regulatory network of ferroptosis, describe the crosstalk between ferroptosis and HCC-related signaling pathways, and elucidate the potential role of ferroptosis in various treatment modalities for HCC, such as systemic therapy, radiotherapy, immunotherapy, interventional therapy and nanotherapy, and applications in the diagnosis and prognosis of HCC, to provide a theoretical basis for the diagnosis and treatment of HCC to effectively improve the survival of HCC patients.
Persistent Identifierhttp://hdl.handle.net/10722/331269
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.988
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHuang, Z-
dc.contributor.authorXia, H-
dc.contributor.authorCui, Y-
dc.contributor.authorYam, JWP-
dc.contributor.authorXu, Y-
dc.date.accessioned2023-09-21T06:54:12Z-
dc.date.available2023-09-21T06:54:12Z-
dc.date.issued2023-02-28-
dc.identifier.citationJournal of Clinical and Translational Hepatology, 2023, v. 11, n. 1, p. 207-218-
dc.identifier.issn2225-0719-
dc.identifier.urihttp://hdl.handle.net/10722/331269-
dc.description.abstractHepatocellular carcinoma (HCC) is one of the most common and highly heterogeneous malignancies worldwide. Despite the rapid development of multidisciplinary treatment and personalized precision medicine strategies, the overall survival of HCC patients remains poor. The limited survival benefit may be attributed to difficulty in early diagnosis, the high recurrence rate and high tumor heterogeneity. Ferroptosis, a novel mode of cell death driven by iron-dependent lipid peroxidation, has been implicated in the development and therapeutic response of various tumors, including HCC. In this review, we discuss the regulatory network of ferroptosis, describe the crosstalk between ferroptosis and HCC-related signaling pathways, and elucidate the potential role of ferroptosis in various treatment modalities for HCC, such as systemic therapy, radiotherapy, immunotherapy, interventional therapy and nanotherapy, and applications in the diagnosis and prognosis of HCC, to provide a theoretical basis for the diagnosis and treatment of HCC to effectively improve the survival of HCC patients.-
dc.languageeng-
dc.publisherXIA & HE Publishing Inc.-
dc.relation.ispartofJournal of Clinical and Translational Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCancer therapy-
dc.subjectFerroptosis-
dc.subjectHepatocellular carcinoma-
dc.subjectMolecular targets-
dc.subjectSorafenib-
dc.titleFerroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma-
dc.typeArticle-
dc.identifier.doi10.14218/JCTH.2022.00255-
dc.identifier.pmid36406319-
dc.identifier.scopuseid_2-s2.0-85141456204-
dc.identifier.volume11-
dc.identifier.issue1-
dc.identifier.spage207-
dc.identifier.epage218-
dc.identifier.isiWOS:000859082700001-
dc.identifier.issnl2225-0719-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats